Investigational Pipeline
Obesity
Compounds still inside company-run clinical trials for weight loss and metabolic disease. None of these are approved for any use. Everything documented here comes from the developer's own registered trials or from published research.
-
Aleniglipron (GSBR-1290)
Investigational compound This compound is not approved for any use. Evidence for aleniglipron comes from Structure Therapeutics’ own published and presented clinical trial data. Aleniglipron (development code GSBR-1290) is an investigational once-daily oral, small-molecule GLP-1 receptor agonist from Structure Therapeutics, being developed for obesity and overweight with weight-related comorbidities. Unlike injectable GLP-1 peptides, it is ... <a title="UBT251" class="read-more" href="https://peptideblog.net/peptides/ubt251/" aria-label="Read more about UBT251">Read more</a>
-
Amycretin
Amycretin is Novo Nordisk's experimental dual GLP-1/amylin receptor agonist for weight loss and type 2 diabetes, with published phase 1b/2a human data showing up to 22% weight loss. Not approved anywhere; phase 3 trials are under way, including AMAZE 9 for the oral tablet.
-
Berobenatide
Berobenatide (MET-097i, PF-08653944) is an experimental GLP-1 receptor agonist built for once-monthly use, developed by Metsera and now owned by Pfizer. Sponsor-reported Phase 2b results show up to 12.3% placebo-adjusted weight loss at week 28.
-
LY4086940
LY4086940, listed by Eli Lilly under the program name GGG Tri-Agonist III, is an investigational oral weight-loss drug. A 219-person phase 1 trial finished in August 2026 and a 460-person phase 2 trial is registered. Structure and doses are undisclosed; never approved.
-
MariTide (Maridebart Cafraglutide)
Investigational compound This compound is not approved for any use. Evidence for MariTide comes from Amgen’s own published and presented clinical trial data, not from independent human trials or vendor sources. MariTide (maridebart cafraglutide, development code AMG 133) is a once-monthly, self-injected antibody-peptide conjugate being developed by Amgen for weight management, with and without type ... <a title="UBT251" class="read-more" href="https://peptideblog.net/peptides/ubt251/" aria-label="Read more about UBT251">Read more</a>
-
NBIP-1968
NBIP-1968 is Neurocrine Biosciences' investigational GLP-1/GIP/glucagon triple agonist for obesity, just entering phase 1 single-ascending-dose testing in August 2026. Its differentiator is a planned future combination with NBIP-2118 aimed at preserving lean mass. No efficacy data exists yet; never approved.
-
Nisotirostide
Nisotirostide (LY3457263) is Eli Lilly's investigational NPY2 receptor agonist, a PYY analog developed as an add-on to GLP-1 drugs like semaglutide and tirzepatide rather than a standalone treatment. Its most advanced trial measures blood sugar control, not weight loss. Not approved anywhere.
-
Petrelintide
Petrelintide (ZP8396) is Zealand Pharma and Roche's investigational amylin analog for weight management, now in phase 3. Phase 2 results reached up to 10.7% weight loss with mostly mild nausea. Not approved anywhere.
-
Taldefgrobep alfa
Investigational compound This compound is not approved for any use. The evidence on this page comes from the developer’s own registered trials, company presentations and trade-press reports, not from peer-reviewed obesity studies. See the full Obesity Pipeline for other compounds at this same stage. Taldefgrobep alfa is an investigational injected protein, not a classic peptide, ... <a title="UBT251" class="read-more" href="https://peptideblog.net/peptides/ubt251/" aria-label="Read more about UBT251">Read more</a>
-
Tradipitant (NEREUS, VLY-686)
Tradipitant (NEREUS) is an oral NK-1 receptor antagonist, FDA approved for motion-induced vomiting and tested in Phase 3 for vomiting after a single 1 mg dose of semaglutide.
-
Trevogrumab
Investigational compound This compound is not approved for any use. The evidence on this page comes from the developer’s registered trials, company releases and trade-press reports; the full phase 2 paper is not yet published. See the full Obesity Pipeline for other compounds at this same stage. Trevogrumab is an investigational antibody from Regeneron that ... <a title="UBT251" class="read-more" href="https://peptideblog.net/peptides/ubt251/" aria-label="Read more about UBT251">Read more</a>
-
UBT251
UBT251 is a GLP-1, GIP and glucagon triple agonist from China's United Laboratories group, licensed outside Greater China to Novo Nordisk. Two phase 2 trials in Cell Metabolism reported 13.6% to 19.7% weight loss at 24 weeks, and phase 3 is under way in China. Not approved anywhere.